Tags : Advancing

Zionexa And Petnet Solutions’ Cerianna (Fluoroestradiol F 18) Receive the

Shots: Cerianna (Fluoroestradiol F 18) is a novel FDA approved molecular imaging agent targeted for PET imaging for detection of estrogen receptor-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer The product will also allow the clinicians better guide treatments for metastatic breast cancer patients and improve patients’ QoL […]Read More

Sanofi Collaborates with Aetion to Leverage its Evidence Platform for

Shots: Sanofi is launching an enterprise-wide project to assimilate its real-world data platform, DARWIN with the Aetion’s Evidence Platform for advancing the efficient use of real-world evidence to facilitate regulatory-grade studies with deep transparency while opening access to new real-world data The collaboration will lead to the transformation of the health care ecosystem following the […]Read More

Arcellx Signs a Development Evaluation and License Agreement with Pfenex

Shots: Pfenex to receive R&D funding along with $2.6M up to $18M as development, regulatory & commercial milestones and royalties on WW sales of products. Arcellx to get access to Pfenex expression technology platform to advance sparX proteins, activating, silencing & reprograming antigen- receptor complex T-cell based therapies Arcellx’s first sparX protein has completed its […]Read More

Exelixis Signs an Exclusive Option and License Agreement with Iconic

Shots: Iconic to receive $7.5M upfront, funds for preclinical development and is eligible for option exercise payment, development, regulatory & commercial milestones, royalties on sales. Exelixis to get an option to license Iconic’s ICON-2 ADC program and will exercise its option at IND filing The focus of the collaboration is to robust Exelixis’s oncology portfolio […]Read More

Abbott Collaborates with NIH on Brain Initiative for Advancing Research

Shots: Abbott to provide its neuromodulation technologies including deep brain stimulation (DBS), spinal cord stimulation (SCS), and dorsal root ganglion (DRG) therapy. NIH to utilize Abbott’s technology for exploring its applications in chronic pain and progressive movement disorders as Parkinson’s disease The focus of the collaboration is to accelerate the application of Abbott’s neurostimulation therapies, […]Read More